<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517566</url>
  </required_header>
  <id_info>
    <org_study_id>CZPL389A2203</org_study_id>
    <nct_id>NCT03517566</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess ZPL389 efficacy and safety in subjects with moderate
      to severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 18, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGA response at Week 16</measure>
    <time_frame>week 16</time_frame>
    <description>IGA is an Investigator's global assessment of severity of atopic dermatitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in EASI score at week 16</measure>
    <time_frame>week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI score and response over time</measure>
    <time_frame>at each visit per protocol, up to week 20</time_frame>
    <description>Eczema Area and Severity Index (EASI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score and response over time</measure>
    <time_frame>at each visit per protocol, up to week 20</time_frame>
    <description>Investigator's Global Assessment (IGA) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of adverse events</measure>
    <time_frame>up to week 20</time_frame>
    <description>Clinical safety and tolerability will be assessed by adverse events monitoring</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of ZPL389</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of ZPL389</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 of ZPL389</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 of ZPL389</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily from baseline until week 16</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389</intervention_name>
    <description>Dose 1 of ZPL389; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389</intervention_name>
    <description>Dose 2 of ZPL389; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389</intervention_name>
    <description>Dose 3 of ZPL389; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389</intervention_name>
    <description>Dose 4 of ZPL389; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must give a written, signed and dated informed consent

          -  Chronic atopic dermatitis present for at least 1 year before Baseline

          -  Moderate to severe atopic dermatitis defined as per EASI, IGA and BSA.

          -  Documented recent history (within 6 months before the screening visit) of inadequate
             response to treatment with topical medications or for whom topical treatments are
             otherwise medically inadvisable

          -  Candidate for systemic treatment

        Exclusion Criteria:

          -  Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis
             disease activity

          -  Use of other investigational drugs within 5 half-lives of enrollment, or within 30
             days or until the expected pharmacodynamic effect has returned to baseline, whichever
             is longer.

          -  History of hypersensitivity to any of the study drug constituents or to drugs of
             similar chemical classes.

          -  Participation in prior ZPL389 studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis, AD, eczema, atopic eczema, itch, pruritus, histamine 4 receptor</keyword>
  <keyword>antagonist, H4R, ZPL389, ZPL389A2203, dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

